Spontaneous Mesotheliomas in F344/N Rats Are Characterized by Dysregulation of Cellular Growth and Immune Function Pathways

Toxicologic Pathology

Volumn 42, Issue 5, 2014, Pages 863-876

  Blackshear, Pamela E ^a   Pandiri, Arun R ^b   Ton, Thai vu T ^c   Clayton, Natasha P ^c   Shockley, Keith R ^c   Peddada, Shyamal D ^c   Gerrish, Kevin E ^c   Sills, Robert C ^c   Hoenerhoff, Mark J ^c  

^a INTEGRATED LABORATORY SYSTEMS   (United States)

^b EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

F344 N rat; Fred PE cells; gene expression; mesothelial cell; mesothelioma; microarray; National Toxicology Program

Indexed keywords

TRANSCRIPTOME; CYTOKINE; GROWTH FACTOR;

ANIMAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; EPITHELIUM; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; MALE; MESOTHELIOMA; METABOLISM; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; RAT; TESTIS; TESTIS TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; GENE; GENE EXPRESSION; HOMEOSTASIS; HOST RESISTANCE; IMMUNE RESPONSE; MESOTHELIUM CELL; MOLECULAR RECOGNITION; NONHUMAN; ONCOGENE; PATTERN RECOGNITION; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNE SYSTEM PROCESSES; MALE; MESOTHELIOMA; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, INBRED F344; TESTICULAR NEOPLASMS; TESTIS; TRANSCRIPTOME;

EID: 84903581719     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313501894     Document Type: Article

References (80)

1. Abbas A. K. Lichtman A. H. (2003). Cellular and Molecular Immunology. Saunders, Philadelphia, PA.
2. Afify A. M. Al-Khafaji B. M. Paulino A. F. Davila R. M. (2002). Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 10, 178–82.
3. Akhurst R. J. Derynck R. (2001). TGF-beta signaling in cancer—A double-edged sword. Trends Cell Biol 11, S44–51.
4. Antony V. B. (2003). Immunological mechanisms in pleural disease. European Respiratory Journal 21, 539–44.
5. Benjamini Y. Hochberg Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stast Soc 57, 289–300.
6. Blobel G. A. Moll R. Franke W. W. Kayser K. W. Gould V. E. (1985). The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 121, 235–47.
7. Bos S. D. Lakenberg N. van der B. R. Houwing-Duistermaat J. J. Kloppenburg M. de Craen A. J. Beekman M. Meulenbelt I. Slagboom P. E. (2012). A genome-wide linkage scan reveals CD53 as an important regulator of innate TNF-alpha levels. Eu J Hum Genet 18, 953–59.
8. Bott M. Brevet M. Taylor B. S. Shimizu S. Ito T. Wang L. Creaney J. Lake R. A. Zakowski M. F. Reva B. Sander C. Delsite R. Powell S. Zhou Q. Shen R. Olshen A. Rusch V. Ladanyi M. (2011). The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43, 668–72.
9. Boutin C. Rey F. (1993). Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 72, 389–93.
10. Bueno R. De Rienzo A. Dong L. Gordon G. J. Hercus C. F. Richards W. G. Jensen R. V. Anwar A. Maulik G. Chirieac L. R. Ho K. F. Taillon B. E. Turcotte C. L. Hercus R. G. Gullans S. R. Sugarbaker D. J. (2010). Second generation sequencing of the mesothelioma tumor genome. PLoS One 5, e10612.
11. Carbone M. Bedrossian C. W. (2006). The pathogenesis of mesothelioma. Sem Diagnos Pathol 23, 56–60.
12. Carbone M. Pass H. I. Miele L. Bocchetta M. (2003). New developments about the association of SV40 with human mesothelioma. Oncogene 22, 5173–80.
13. Cargnello M. Roux P. P. (2011). Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75, 50–83.
14. Ch’ng E. S. Tuan Sharif S. E. Jaafar H. (2013). In human invasive breast ductal carcinoma, tumor stromal macrophages and tumor nest macrophages have distinct relationships with clinicopathological parameters and tumor angiogenesis. Virchows Arch 462, 257–67.
15. Colotta F. Allavena P. Sica A. Garlanda C. Mantovani A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30, 1073–81.
16. Crosby L. M. Hyder K. S. DeAngelo A. B. Kepler T. B. Gaskill B. Benavides G. R. Yoon L. Morgan K. T. (2000). Morphologic analysis correlates with gene expression changes in cultured F344 rat mesothelial cells. Toxicol Appl Pharmacol 169, 205–21.
17. Cuadrado A. Nebreda A. R. (2010). Mechanisms and functions of p38 MAPK signalling. Biochem J 429, 403–17.
18. Efron B. Tibshirani R. (1993). Hypothesis testing with the bootstrap. In An Introduction to the Bootstrap (D.R. Cox, D.V. Hinkley, N. Reid, D.B. Rubin, and B.W. Silverman, eds.), pp. 220-236. Chapman & Hall/CRC Monographs on Statistics & Applied Probability, New York, NY.
19. Feng F. Wu Y. Zhang S. Liu Y. Qin L. Yan Z. Wu W. (2012). Macrophages facilitate coal tar pitch extract-induced tumorigenic transformation of human bronchial epithelial cells mediated by NF-kappaB. PLoS One 7, e51690.
20. Gautier L. Bolstad B. M. Irizarry R. A. (2003). Affy-Analysis of Affymetrix GeneCHip probe level data. Bioinformatics 20, 307–15.
21. Gordon G. J. Rockwell G. N. Jensen R. V. Rheinwald J. G. Glickman J. N. Aronson J. P. Pottorf B. J. Nitz M. D. Richards W. G. Sugarbaker D. J. Bueno R. (2005). Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166, 1827–40.
22. Greenlee-Wacker M. C. Galvan M. D. Bohlson S. S. (2012). CD93: Recent advances and implications in disease. Curr Drug Targets 13, 411–20.
23. Gueugnon F. Leclercq S. Blanquart C. Sagan C. Cellerin L. Padieu M. Perigaud C. Scherpereel A. Gregoire M. (2011). Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol 178, 1033–42.
24. Gullu G. Karabulut S. Akkiprik M. (2012). Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer 31, 266–80.
25. Hall W. C. Boorman G. Eustis S. Elwell M. R. Montgomery C. A. MacKenzie W. F. (1990). Peritoneum, retroperitoneum, mesentery, and abdominal cavity. In Pathology of the Fischer Rat. (Boorman G.A. Eustis S.L. Elwell M.R. Montgomery C.A. MacKenzie W.F. eds.), pp. 63–69. Academic Press, San Diego, CA.
26. Hanahan D. Weinberg R. A. (2011). Hallmarks of cancer: The next generation. Cell 144, 646–74.
27. Hu Q. Akatsuka S. Yamashita Y. Ohara H. Nagai H. Okazaki Y. Takahashi T. Toyokuni S. (2010). Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 90, 360–73.
28. Irizarry R. A. Bolstad B. M. Collin F. Cope L. M. Hobbs B. Speed T. P. (2003). Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res 31, e15.
29. Izzi V. Masuelli L. Tresoldi I. Foti C. Modesti A. Bei R. (2012). Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 322, 18–34.
30. Jantz M. A. Antony V. B. (2008). Pathophysiology of the pleura. Respiration 75, 121–33.
31. Jean D. Daubriac J. Le Pimpec-Barthes F. Galateau-Salle F. Jaurand M. C. (2012). Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 136, 277–93.
32. Jia J. Bai Y. Fu K. Sun Z. J. Chen X. M. Zhao Y. F. (2008). Expression of allograft inflammatory factor-1 and CD68 in haemangioma: Implication in the progression of haemangioma. Bri J Dermatol 159, 811–19.
33. Kaufman A. J. Pass H. I. (2008). Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther 8, 293–303.
34. Kim Y. Ton T. V. DeAngelo A. B. Morgan K. Devereux T. R. Anna C. Collins J. B. Paules R. S. Crosby L. M. Sills R. C. (2006). Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats. Toxicol Appl Pharmacol 214, 144–51.
35. Kupryjanczyk J. Karpinska G. (1998). Desmin expression in reactive mesothelium: A potential aid in evaluation of gynecologic specimens. Int J Gynecol Pathol 17, 123–28.
36. Letterio J. J. Roberts A. B. (1998). Regulation of immune responses by TGF-beta. Ann Rev Immunol 16, 137–61.
37. Litvinov S. V. Balzar M. Winter M. J. Bakker H. A. Briaire-de B. I. Prins F. Fleuren G. J. Warnaar S. O. (1997). Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139, 1337–48.
38. Liu S. Tan W. Y. Chen Q. R. Chen X. P. Fu K. Zhao Y. Y. Chen Z. W. (2008). Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth. Cancer Sci 99, 952–57.
39. Mackay A. M. Tracy R. P. Craighead J. E. (1987). Intermediate filament proteins in asbestos-induced mesotheliomas of the rat. Cancer Res 47, 5461–68.
40. Madison L. D. Bergstrom-Porter B. Torres A. R. Shelton E. (1979). Regulation of surface topography of mouse peritoneal cells. Formation of microvilli and vesiculated pits on omental mesothelial cells by serum and other proteins. J Cell Biol 82, 783–97.
41. Maetzel D. Denzel S. Mack B. Canis M. Went P. Benk M. Kieu C. Papior P. Baeuerle P. A. Munz M. Gires O. (2009). Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11, 162–71.
42. Maniecki M. B. Etzerodt A. Ulhoi B. P. Steiniche T. Borre M. Dyrskjot L. Orntoft T. F. Moestrup S. K. Moller H. J. (2012). Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 131, 2320–31.
43. Matsuzaki H. Maeda M. Lee S. Nishimura Y. Kumagai-Takei N. Hayashi H. Yamamoto S. Hatayama T. Kojima Y. Tabata R. Kishimoto T. Hiratsuka J. Otsuki T. (2012). Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol 2012, 492–608.
44. Mullink H. Henzen-Logmans S. C. Alons-van Kordelaar J. J. Tadema T. M. Meijer C. J. (1986). Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 52, 55–65.
45. Nasreen N. Mohammed K. A. Hardwick J. Van Horn R. D. Sanders K. Kathuria H. Loghmani F. Antony V. B. (2002). Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: Role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res 13, 71–78.
46. NTP (National Toxicology Program). (2011). NTP Historical Controls Report: All Routes and Vehicles, F344/N Rats, May 2011, available at http://ntp-server.niehs.nih.gov/?objectid=92E705C7-F1F6-975E-72D23026B1645EB9.
47. Ochi A. Graffeo C. S. Zambirinis C. P. Rehman A. Hackman M. Fallon N. Barilla R. M. Henning J. R. Jamal M. Rao R. Greco S. Deutsch M. Medina-Zea M. V. Bin Saeed U. Ego-Osuala M. O. Hajdu C. Miller G. (2012). Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 122, 4118–29.
48. Patriarca C. Macchi R. M. Marschner A. K. Mellstedt H. (2012). Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev 38, 68–75.
49. Peddada S. Harris S. Zajd J. Harvey E. (2005). ORIOGEN: Order restricted inference for ordered gene expression data. Bioinformatics 21, 3933–34.
50. Pollard J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4, 71–78.
51. Remon J. Lianes P. Martinez S. Velasco M. Querol R. Zanui M. (2012). Malignant mesothelioma: New insights into a rare disease. Cancer Treat Rev 39, 584–91.
52. Robinson B. W. Lake R. A. (2005). Advances in malignant mesothelioma. N Eng J Med 353, 1591–603.
53. Romagnoli S. Fasoli E. Vaira V. Falleni M. Pellegrini C. Catania A. Roncalli M. Marchetti A. Santambrogio L. Coggi G. Bosari S. (2009). Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol 174, 762–70.
54. Ryan P. J. Oates J. L. Crocker J. Stableforth D. E. (1997). Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer. Resp Med 91, 57–60.
55. Sato A. Sekine M. Virgona N. Ota M. Yano T. (2012). Yes is a central mediator of cell growth in malignant mesothelioma cells. Oncol Rep 28, 1889–93.
56. Sekido Y. (2013). Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34, 1413–1419.
57. Shabo I. Svanvik J. (2011). Expression of macrophage antigens by tumor cells. Adv Exp Med Biol 714, 141–50.
58. Shield P. W. Callan J. J. Devine P. L. (1994). Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 11, 237–45.
59. Swain W. A. O’Byrne K. J. Faux S. P. (2004). Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. Am J Physiol Lung Cell Mol Physiol 286, L859–65.
60. Takeuchi O. Akira S. (2010). Pattern recognition receptors and inflammation. Cell 140, 805–20.
61. Tang B. Vu M. Booker T. Santner S. J. Miller F. R. Anver M. R. Wakefield L. M. (2003). TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112, 1116–24.
62. Testa J. R. Cheung M. Pei J. Below J. E. Tan Y. Sementino E. Cox N. J. Dogan A. U. Pass H. I. Trusa S. Hesdorffer M. Nasu M. Powers A. Rivera Z. Comertpay S. Tanji M. Gaudino G. Yang H. Carbone M. (2011). Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43, 1022–25.
63. Tomasetti M. Amati M. Santarelli L. Alleva R. Neuzil J. (2009). Malignant mesothelioma: Biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2, 190–206.
64. Traves P. G. Luque A. Hortelano S. (2012). Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm 2012, 568–783.
65. Tsujimura T. Torii I. Sato A. Song M. Fukuoka K. Hasegawa S. Nakano T. (2012). Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol 17, 40–47.
66. Turovskaya O. Foell D. Sinha P. Vogl T. Newlin R. Nayak J. Nguyen M. Olsson A. Nawroth P. P. Bierhaus A. Varki N. Kronenberg M. Freeze H. H. Srikrishna G. (2008). RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29, 2035–43.
67. Voelcker V. Gebhardt C. Averbeck M. Saalbach A. Wolf V. Weih F. Sleeman J. Anderegg U. Simon J. (2008). Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 17, 100–07.
68. Walker C. Everitt J. Barrett J. C. (1992). Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Ind Med 21, 253–73.
69. Whitaker D. Papadimitriou J. M. Walters M. N. (1980). The mesothelium: A histochemical study of resting mesothelial cells. J Pathol 132, 273–84.
70. Whitson B. A. Kratzke R. A. (2006). Molecular pathways in malignant pleural mesothelioma. Cancer Lett 239, 183–89.
71. Wu J. Yang X. Zhang Y. F. Wang Y. N. Liu M. Dong X. Q. Fan J. J. Yu X. Q. (2010). Glucose-based peritoneal dialysis fluids downregulate toll-like receptors and trigger hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells. Clin Vaccine Immunol 17, 757–63.
72. Xie W. Huang Y. Guo A. Wu W. (2010). Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells. PLoS One 5, e10850.
73. Xu J. Futakuchi M. Shimizu H. Alexander D. B. Yanagihara K. Fukamachi K. Suzui M. Kanno J. Hirose A. Ogata A. Sakamoto Y. Nakae D. Omori T. Tsuda H. (2012). Multi-walled carbon nanotubes translocate into the pleural cavity and induce visceral mesothelial proliferation in rats. Cancer Sci 103, 2045–50.
74. Yang H. Testa J. R. Carbone M. (2008). Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 9, 147–57.
75. Yang L. Pang Y. Moses H. L. (2010). TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31, 220–27.
76. Yu L. Wang L. Chen S. (2012). Exogenous or endogenous toll-like receptor ligands: Which is the MVP in tumorigenesis? Cell Mol Life Sci 69, 935–49.
77. Yung S. Chan T. M. (2007). Mesothelial cells. Perit Dial Int 27 S110–15.
78. Yung S. Chan T. M. (2011). Pathophysiology of the peritoneal membrane during peritoneal dialysis: The role of hyaluronan. J Biomed Biotechnol 2011, 180–594.
79. Yunta M. Lazo P. A. (2003). Apoptosis protection and survival signal by the CD53 tetraspanin antigen. Oncogene 22, 1219–24.
80. Zhong J. Lardinois D. Szilard J. Tamm M. Roth M. (2011). Rat mesothelioma cell proliferation requires p38delta mitogen activated protein kinase and C/EBP-alpha. Lung Canr 73, 166–70.